

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/511,537	First Named Inventor: Hanson
371 Filing Date: October 15, 2004	Attorney Docket No.: 100647-1P US
Examiner: Mark L. Berch	Group Art Unit: 1624
Customer No.: 22466	Confirmation No.: 4417
Title: Thioxanthine Derivatives as Myeloperoxidase Inhibitors	

Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

**REQUEST PURSUANT TO 37 C.F.R. § 1.48(b) TO DELETE ORIGINALLY NAMED INVENTORS DUE TO CLAIM AMENDMENTS**

Pursuant to 37 C.F.R. § 1.48(b), Applicants herein request that originally named inventors Sverker Hanson and Gunnar Nordvall be deleted as inventors because neither Sverker Hanson, nor Gunnar Nordvall are inventor(s) of the invention now being claimed in claims 13-14, 19-22, and 27-28.

The Office is hereby authorized to charge the \$130.00 fee due under 37 C.F.R. § 1.17(i) to Deposit Account No. 26-0166.

Although Applicants believe no additional fees are due, the Commissioner is hereby authorized to charge any deficiency in fees or credit any overpayment to deposit account No. 26-0166, referencing Attorney Docket No. 100647-1P US.

A duplicate of this paper is attached.

Respectfully submitted,

/Jacqueline M. Cohen/

Global Intellectual Property,  
 Patents, AstraZeneca  
 1800 Concord Pike  
 Wilmington  
 DE-19850-5437

Name: Jacqueline M. Cohen  
 Dated: 1/15/2008  
 Reg. No.: 51,574  
 Phone No.: 302-885-4269